15 Aug 2025
The UK’s National Institute for Health and Care Excellence (NICE) has announced it will seek further guidance on whether new treatment givinostat should be made routinely available on the NHS. NICE held its initial committee meeting to appraise the drug in July,...
2 Apr 2025
Pictured: DRF director of operations Sheli Rodney (second from right) with fellow members of the Psychosocial Working Group: disability and education specialist Dr Janet Hoskin, DMD Care UK manager Cathy Turner, Pathfinders Neuromuscular Alliance trustee Benjamin...
10 Dec 2024
New medicine for Duchenne muscular dystrophy, funded by Duchenne Research Fund and patient groups, becomes first approved treatment in the UK for all patients with Duchenne The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on...
25 Nov 2024
We were invited to join the celebrations for the John Walton Muscular Dystrophy Research Centre’s 10th anniversary in Newcastle. The late Lord John Walton was a pioneering neurologist who made an enormous impact on muscular dystrophy diagnosis and treatment. The...
29 Feb 2024
On 29th February, Rare Disease Day, we were pleased to be part of the 2024 national meeting for DMD Care UK. More than 130 clinicians and 25 patient representatives are now involved in DMD Care UK, giving their time and expertise across no fewer than 13 working groups...
1 Feb 2024
We are pleased to share that DMD Care UK’s new respiratory guidance has been endorsed by the British Thoracic Society and published in Thorax, an international peer-reviewed medical journal with a respiratory focus. It is published by the BMJ Group on behalf of...
18 Dec 2023
The European Medicines Agency (EMA) has granted marketing authorisation for vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. It is approved for all people with Duchenne, irrespective of their underlying...
28 Oct 2023
The US FDA (Food and Drug Administration) has approved Vamorolone for the treatment of Duchenne muscular dystrophy in children and adults aged 2 and over. It will be sold under the brand name Agamree and is expected to be available in the US in early 2024. This...
13 Oct 2023
We are pleased to share that the EMA (European Medicines Agency) has recommended the approval of Vamorolone – the first ever treatment for all patients with Duchenne. Vamorolone is an alternative to corticosteroids. It was developed with the aim of maximising...
28 Feb 2023
On Rare Disease Day, watch Eli Crossley, son of our friend and Duchenne UK co-founder Emily, as he talks about – and demonstrates – the amazing technological developments that are being trialled for children with Duchenne muscular dystrophy. The ‘smart...